文献速递胸部肿瘤消化系统肿瘤泌尿男性生殖肿瘤

肾素-血管紧张素-醛固酮系统抑制剂与接受免疫检查点抑制剂治疗的高血压患者的生存

Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors.
PubMed 文献 · Eur J Cancer · 2022-01-19

这项回顾性研究在单一学术网络纳入10,903例接受免疫检查点抑制剂治疗的患者,其中5910例使用降压药,3426例合用肾素-血管紧张素-醛固酮系统(RAAS)抑制剂,2484例使用其他降压药。Cox模型显示合用RAAS抑制剂与更好的总生存相关(HR 0.92,95%CI 0.85-0.99,P=0.032)。

要点

  • 在5910例使用降压药的患者中,3426例合用RAAS抑制剂,2484例使用其他降压药。
  • 合用RAAS抑制剂与更好的总生存相关(HR 0.92,95%CI 0.85-0.99,P=0.032)。
  • 胃肠道癌(HR 0.82,95%CI 0.67-1.01,P=0.057)和泌尿生殖系统癌(HR 0.81,95%CI 0.64-1.01,P=0.067)的总生存改善未达统计学显著。

核心结论

  • 在这项大型回顾性研究中,接受ICI治疗期间合用RAAS抑制剂的高血压患者总生存更好。
  • 这一获益主要在胃肠道癌和泌尿生殖系统癌患者中观察到。
  • 需要前瞻性随机试验进一步评估和明确RAAS抑制剂在接受ICI治疗的癌症患者中的获益。

研究设计与样本

  • 回顾性研究,纳入单一学术网络中所有接受ICI治疗的患者。
  • 共10,903例患者,其中5910例使用任何降压药物。
  • 使用降压药的患者中,3426例在ICI治疗期间处方RAAS抑制剂,2484例处方其他降压药物。
  • 主要结局为整个队列及按癌症类型分亚组的总生存。

主要发现

  • 胸部肿瘤(34%)和黑色素瘤(16%)是最常见的癌症类型。
  • 处方RAAS抑制剂者年龄更大、男性更多、心血管危险因素更多。
  • Cox比例风险模型显示,合用RAAS抑制剂与更好的总生存相关(HR 0.92,95%CI 0.85-0.99,P=0.032)。
  • 胃肠道癌患者总生存改善未达统计学显著(HR 0.82,95%CI 0.67-1.01,P=0.057)。
  • 泌尿生殖系统癌患者总生存改善未达统计学显著(HR 0.81,95%CI 0.64-1.01,P=0.067)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性研究。
  • 原文为单一学术网络的研究。
  • 需要前瞻性随机试验进一步评估和明确RAAS抑制剂在接受ICI治疗的癌症患者中的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical studies indicate that the concurrent use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) may improve outcomes in broad groups of patients with cancer. There are limited data on the association between the use of RAAS inhibitors and outcomes among patients treated with immune checkpoint inhibitors (ICIs). METHODS: We performed a retrospective study of all patients treated with an ICI in a single academic network. Of 10,903 patients, 5910 were on any anti-hypertensive medication. Of those on anti-hypertensive therapy, 3426 were prescribed a RAAS inhibitor during ICI treatment, and 2484 were prescribed other anti-hypertensive medications. The primary outcome was overall survival in the entire cohort and in sub-groups by cancer types. RESULTS: Thoracic cancer (34%) and melanoma (16%) were the most common types of cancer. Those prescribed a RAAS inhibitor were older, more frequently male, and had more cardiovascular risk factors. In a Cox proportional hazard model, the concurrent use of RAAS inhibitors was associated with better overall survival (hazard ratio (HR):0.92, [95% Confidence Interval (CI):0.85-0.99], P = .032). Patients with gastrointestinal (HR:0.82, [95% CI: 0.67-1.01], P = .057) and genitourinary cancer (HR:0.81, [95% CI:0.64-1.01], P = .067) had a non-statistically significant better overall survival. CONCLUSIONS: In this large retrospective study, patients with hypertension who were concomitantly taking a RAAS inhibitor during ICI therapy had better overall survival. This benefit was primarily noted among patients with gastrointestinal and genitourinary cancers. Prospective randomized trials are warranted to further evaluate and specify the benefit of RAAS inhibitors in patients with cancer who receive ICI therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Drobni ZD, Michielin O, Quinaglia T, et al. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022. PMID: 35065368. doi:10.1016/j.ejca.2021.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。